The document summarizes the Strategic Timing of Antiretroviral Treatment (START) study, which aims to determine if initiating antiretroviral therapy (ART) earlier in HIV infection reduces morbidity and mortality compared to deferring ART until the CD4 count declines below 350 cells/mm3. The START study plans to enroll 4000 HIV-infected but asymptomatic adults with CD4 counts over 500 cells/mm3 and randomly assign them to either immediate ART or deferred ART. The primary endpoint is AIDS, serious non-AIDS events, or death. Secondary endpoints include individual disease outcomes and adverse events.